Lupin gains as its arm receives USFDA approval for generic Rifadin capsules

Lupin’s - US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Rifampin Capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (USFDA).

Lupin’s Rifampin Capsules USP, 150 mg and 300 mg are the AB‐rated generic equivalent of Sanofi Aventis’ Rifadin Capsules 150 mg and 300 mg strengths. Rifampin Capsules is indicated for the treatment of all forms of Tuberculosis and for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx.

Rifadin Capsules had annual US sales of approximately $18.5 million, as per IMS MAT March 2013. Lupin is one of the pioneers in the fight against Tuberculosis and holds global leadership positions in the Anti‐TB segment.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.